Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database
PLOS ONE · 11.06.2024 · 19 (6) · e0305320
DOI: 10.1371/journal.pone.0305320 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift PLOS ONE, online erschienen am 11.06.2024. Verfasst von Satoshi Yamate und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Alanine, Anti-Inflammatory Agents, Non-Steroidal, Quinolones, Gastrointestinal Hemorrhage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Fusion Oriented REsearch for disruptive Science and Technology.
Abstract (Originalsprache)
Background
Rebamipide has been widely co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) in Japan for decades. This study aimed to evaluate the effectiveness of rebamipide in preventing upper gastrointestinal bleeding in new users of NSAIDs without risk factors of NSAID-induced ulcers other than age.
Methods
A nested case-control study was conducted using medical claims data of 1.66 million inhabitants of 17 municipalities participating in Japan’s Longevity Improvement & Fair Evidence study. The cohort entry (t 0 ) corresponded to a new user of NSAIDs for osteoarthritis or low back pain. Patients with risk factors of NSAID-induced ulcers other than age were excluded. Cases were defined as patients who underwent gastroscopy for upper gastrointestinal bleeding (occurrence date was defined as index date). A maximum of 10 controls were selected from non-cases at the index date of each case by matching sex, age, follow-up time, and type and dosage of NSAIDs. Exposure to rebamipide was defined as prescription status from t 0 to index date: Non-user (rebamipide was not co-prescribed during the follow-up period), Continuous-user (rebamipide was co-prescribed from t 0 with the same number of tablets as NSAIDs), and Irregular-user (neither Non-user nor Continuous-user). Conditional logistic regression analysis was conducted to estimate each category’s odds ratio compared to non-users.
Findings
Of 67,561 individuals who met the inclusion criteria, 215 cases and 1,516 controls were selected. Compared with that of Non-users, the odds ratios and 95% confidence interval were 0.65 (0.44–0.96) for Continuous-users and 2.57 (1.73–3.81) for Irregular-users.
Conclusions
Continuous co-prescription of rebamipide significantly reduced the risk of upper gastrointestinal bleeding in an Asian cohort of new users of NSAIDs with osteoarthritis or low back pain without risk factors other than age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Data Science, Section of Clinical Epidemiology, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Satoshi Yamate, Haruhisa Fukuda, Satoshi Hamai
Förderung
- Japan Society for the Promotion of Science
- Fusion Oriented REsearch for disruptive Science and Technology
Zitieren
APA
Yamate, S., Ishiguro, C., Fukuda, H., Hamai, S., & Nakashima, Y. (2024). Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database. PLOS ONE, 19(6), e0305320. https://doi.org/10.1371/journal.pone.0305320
Vancouver
Yamate S, Ishiguro C, Fukuda H, Hamai S, Nakashima Y. Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database. PLOS ONE. 2024;19(6):e0305320. doi:10.1371/journal.pone.0305320
BibTeX
@article{Yamate2024,
author = {Yamate, Satoshi and Ishiguro, Chieko and Fukuda, Haruhisa and Hamai, Satoshi and Nakashima, Yasuharu},
title = {Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0305320},
doi = {10.1371/journal.pone.0305320}
}
EUVIMED